MetaCap

FibroBiologics (FBLG) vs Kyntra Bio (KYNB)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

FibroBiologics is the larger company by market cap ($6.3 million vs $6.3 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

FBLG-38.16%KYNB-74.55%
+4%-37%-78%
Oct 7, 20261 yearNov 20, 2026
FBLG-37.61%KYNB-74.47%
+4%-37%-78%
Oct 5, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

FBLG versus KYNB key metrics
MetricFBLGKYNB
Share price$0.705$1.56
Market cap$6.34M$6.32M
1-day change-15.06%-13.33%
YTD return—-82.23%
1-year return—-81.47%
5-year return—-99.49%
EPS (TTM)$-2.51$-4.35
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$6.44M
Revenue growth (YoY)—-78.26%
Net income (latest FY)$-18.65M$183.45M
Gross margin—91.37%
Operating margin—-712.66%
Net margin—2848.63%
52-week high$9.60$10.47
52-week low$0.62$1.56
Distance from 52-week high-92.66%-85.10%
Analyst consensusnonenone
Avg. price target upside+1673.05%+2442.95%
Average volume160.05K29.96K
Shares outstanding8.99M4.05M
Employees1534
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About FibroBiologics

FBLG stock →

FibroBiologics, Inc., a clinical-stage biotechnology company, engages in the development and commercialization of fibroblast-based therapies for patients suffering from chronic diseases. The company's product pipeline includes CYWC628 which has completed pre-clinical trial for the treatment of wound healing; CYMS101 which has completed Phase 1 trial for the treatment of multiple sclerosis; CybroCell for the treatment of degenerative disc disease; and CYPS317 for the treatment of psoriasis.

Health Care · Biotechnology: Pharmaceutical Preparations · 15 employees

About Kyntra Bio

KYNB stock →

Kyntra Bio, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing FG-3246, a potential antibody-drug conjugate targeting CD46, for the treatment of metastatic castration-resistant prostate cancer and other cancers.

Health Care · Biotechnology: Pharmaceutical Preparations · 34 employees

FBLG vs KYNB FAQ

Which is bigger, FibroBiologics or Kyntra Bio?

FibroBiologics (FBLG) is larger, with a market capitalization of $6.34M compared with $6.32M for Kyntra Bio (KYNB).

Are FibroBiologics and Kyntra Bio in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons